PTL is a well-known NF-κB inhibitor and has shown downregulation of NF-κB level in a type 2 diabetes rat model (Khare et al. 2017), and in a TBI mouse model (Ding et al. 2022). Here, NFKB1 is linked to type 2 diabetes mellitus.